KDR and cancer: After the FDA’s approval of the VEGFR-2 inhibitor Sunitinib, medicinal chemists have paid special attention to the identification of new isatin-based anti-cancer candidates targeting VEGFR-2 kinase [32,33,34,35,36,37,38,39,40,41,42,43,44].